Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Chronic Inflammation: Introduction01:12

Chronic Inflammation: Introduction

Chronic inflammation is a prolonged, dysregulated immune response that persists for weeks to years when the inciting stimulus is difficult to eradicate or when self‑antigens drive ongoing reactivity. Morphologically, it is defined by mononuclear cell infiltration, progressive tissue destruction, and concurrent attempts at healing via angiogenesis and fibrosis. Compared with acute inflammation, edema is less prominent while cellular infiltration predominates; triggers include persistent...
Inflammatory Response01:28

Inflammatory Response

An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Free IL-18 in NLRC4-associated autoinflammatory disease without macrophage activation syndrome.

Rheumatology (Oxford, England)·2026
Same authorSame journal

Advances in targeting IL-1 family cytokines for the treatment of inflammatory diseases.

Nature reviews. Rheumatology·2026
Same author

Machine Learning to Predict Remission Between 6 and 24 Months in Rheumatoid Arthritis: Insights From JAK, an International Registry Collaboration.

Arthritis & rheumatology (Hoboken, N.J.)·2026
Same author

Development and validation of clinical criteria for the definition of disease activity in adult-onset Still's disease: a cohort study.

The Lancet. Rheumatology·2026
Same author

IL1R2 Deficiency Unleashes Neutrophil-Mediated Antitumor Potential in Sarcoma.

Cancer immunology research·2026
Same author

[Rheumatoid arthritis pathogenesis. From susceptibility to autoimmunity, and arthritis].

Revue medicale suisse·2026

Related Experiment Video

Updated: Jun 16, 2026

Accurate and Simple Measurement of the Pro-inflammatory Cytokine IL-1β using a Whole Blood Stimulation Assay
06:29

Accurate and Simple Measurement of the Pro-inflammatory Cytokine IL-1β using a Whole Blood Stimulation Assay

Published on: March 1, 2011

IL-1 pathways in inflammation and human diseases.

Cem Gabay1, Céline Lamacchia, Gaby Palmer

  • 1Division of Rheumatology, University Hospitals of Geneva & Department of Pathology-Immunology, University of Geneva School of Medicine, 26 Avenue Beau-Séjour, 1211 Geneva 14, Switzerland. cem.gabay@hcuge.ch

Nature Reviews. Rheumatology
|February 24, 2010
PubMed
Summary

Interleukin-1 (IL-1) inhibitors show promise for treating various inflammatory conditions. While modest in rheumatoid arthritis, IL-1 blockers are effective in hereditary autoinflammatory diseases and show potential in other conditions like type 2 diabetes.

More Related Videos

Characterization of Immune Cells and Proinflammatory Mediators in the Pulmonary Environment
09:00

Characterization of Immune Cells and Proinflammatory Mediators in the Pulmonary Environment

Published on: June 24, 2020

Related Experiment Videos

Last Updated: Jun 16, 2026

Accurate and Simple Measurement of the Pro-inflammatory Cytokine IL-1β using a Whole Blood Stimulation Assay
06:29

Accurate and Simple Measurement of the Pro-inflammatory Cytokine IL-1β using a Whole Blood Stimulation Assay

Published on: March 1, 2011

Characterization of Immune Cells and Proinflammatory Mediators in the Pulmonary Environment
09:00

Characterization of Immune Cells and Proinflammatory Mediators in the Pulmonary Environment

Published on: June 24, 2020

Area of Science:

  • Immunology
  • Inflammation Biology

Background:

  • Interleukin-1 (IL-1) is a key regulator of inflammatory processes, existing as IL-1alpha and IL-1beta.
  • Naturally occurring inhibitors like IL-1 receptor antagonist (IL-1Ra) control IL-1 effects.
  • Previous IL-1 inhibitor trials in rheumatoid arthritis yielded modest results.

Purpose of the Study:

  • To review the efficacy of IL-1 inhibitors across a spectrum of IL-1-driven diseases.
  • To explore the therapeutic potential of IL-1 blockade beyond traditional inflammatory conditions.

Main Methods:

  • Literature review of studies involving IL-1 inhibitors.
  • Analysis of clinical outcomes in patients with various inflammatory and autoinflammatory diseases.
  • Examination of the role of IL-1beta processing in crystal-induced arthritis.

Main Results:

  • IL-1 antagonists show significant benefits in hereditary autoinflammatory conditions (e.g., cryopyrinopathies, IL-1Ra deficiency).
  • Successful IL-1 blockade reported in Schnizler syndrome, systemic-onset juvenile idiopathic arthritis, and adult Still disease.
  • IL-1 targeting shows preliminary efficacy in type 2 diabetes and smoldering myeloma.

Conclusions:

  • IL-1 inhibitors are highly effective for hereditary autoinflammatory diseases characterized by excessive IL-1 signaling.
  • The therapeutic applications of IL-1 inhibitors are expanding to include crystal-induced arthritis and other non-hereditary inflammatory conditions.
  • Targeting IL-1 represents a promising therapeutic strategy for a growing range of IL-1-driven diseases.